Evaluation of ALN-APP Safety and Tolerability in Early-Onset Alzheimer's Disease Patients

The primary objective of this study is to evaluate the **safety** and **tolerability** of ALN-APP in patients diagnosed with **early-onset Alzheimer's disease (EOAD)**. This is clinically relevant as it aims to determine the potential adverse effects and overall acceptability of the investigational product in a population affected by EOAD, a condition characterized by the early manifestation of Alzheimer's symptoms, which can significantly impact quality of life and disease progression. Understanding the safety profile of ALN-APP is crucial for its potential development as a therapeutic option for this patient group.

The clinical trial involves a total of **53 participants** diagnosed with **early-onset Alzheimer's disease (EOAD)**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected to represent a vulnerable population, although specific selection criteria have not been disclosed. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and tolerability of a novel investigational product in patients diagnosed with **early-onset Alzheimer's disease (EOAD)**. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from October 18, 2022, to June 3, 2027, encompassing both the recruitment and follow-up periods.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to confirm the participant's suitability for the trial. Following successful screening, participants will be randomized into different study arms. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess the investigational product's effects, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the investigational product's safety and tolerability.

The expected length of participant involvement in the trial is determined by the study protocol, which outlines the frequency and timing of visits. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are structured to prioritize participant safety while achieving the study's scientific objectives.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date for the trial is October 18, 2022, with an anticipated end date of June 3, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of pharmacokinetics and pharmacodynamics, which may include measuring **biomarker** levels or other relevant physiological responses. The trial will likely employ validated scales and laboratory tests to collect and analyze data at predetermined intervals throughout the study duration. The methodology will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments.